AbbVie licenses Nxera's EP4 gut-targeting IBD program for up to $1.47 billion

AbbVie announced a licensing agreement with Nxera Pharma to acquire rights to its EP4 receptor agonist program aimed at inflammatory bowel disease.

The deal includes an upfront payment of $100 million, with additional development and commercial milestones that could bring total payments to $1.47 billion.

Nxera will transfer global rights through its UK subsidiary, while the Tokyo-based company will continue certain responsibilities. The partnership expands AbbVie's pipeline in gut-targeted therapies.